<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097017</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-14-0801-AS-CTIL</org_study_id>
    <nct_id>NCT02097017</nct_id>
  </id_info>
  <brief_title>Prophylactic Lidocaine Spray for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Second Trimester Dilatation and Evacuation</brief_title>
  <official_title>Prophylactic Lidocaine Spray for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Second Trimester Dilatation and Evacuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <brief_summary>
    <textblock>
      To examine whether application of lidocaine spray in cervical preparation for second
      trimester dilatation and evacuation alleviates pain and is superior to current protocol of
      preparation without analgesia and superior to placebo.

      a double- blind, randomized, placebo- controlled trial, performed at a single tertiary
      medical center. Eligible participants aged 18 and older and about to undergo dilation &amp;
      evacuation of the uterus between 12 to 24 weeks of gestation. Participants will be randomized
      using computer generated allocation to receive 10% Xylocaine (lidocaine group) spray or
      normal saline 0.9% (placebo group), applied identically topically to the endocervix and
      ectocervix before laminaria insertion. The primary outcome will be the participant's reported
      pain score immediately after the first laminaria was inserted as measured on a 10 cm visual
      analog scale (VAS). Secondary outcomes wiil be reported pain scores at speculum removal, 15
      minutes after speculum insertion and immediately before the D&amp;E procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Actual">August 1, 2018</completion_date>
  <primary_completion_date type="Actual">August 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain immediately after inserton of first laminaria</measure>
    <time_frame>immediately after first laminaria insertion</time_frame>
    <description>Women's reported VAS pain score immediately after the insertion of the first laminaria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reported pain afer speculum removal, 15 minutes after speculum inserion and before D&amp;E</measure>
    <time_frame>After speculum removal, 15 minutes after speculum insertion and before D&amp;E</time_frame>
    <description>Reported VAS pain at speculum removal, 15 minutes after speculum insertion and before D&amp;E</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Pain Alleviation</condition>
  <condition>Dilatation and Evacuation</condition>
  <condition>Laminaria Placement</condition>
  <arm_group>
    <arm_group_label>lidocaine spray group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>will local application of lidocaine to the cervix alleviate pain of laminaria insertion</description>
    <arm_group_label>lidocaine spray group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo comparator</intervention_name>
    <arm_group_label>placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Informed consent

               -  Women with a gestational age of 12-24 weeks by last menstrual period.

        Exclusion Criteria:

          -  • CRL assesed by ultrasound as &lt;10 weeks

               -  Clinical Uterine size &gt;24 weeks

               -  Fetus Bi Parietal Diameter &gt; 50 mm

               -  Known amide allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 23, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Avi Shina MD</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>lidocaine</keyword>
  <keyword>laminaria</keyword>
  <keyword>dilatation and evacuation</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

